You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Driving the shift is a belief that standard STR testing is not always a reliable tool for determining complex family relationships.
The firm can now tell customers if their genotypes may impact their response to clopidogrel and citalopram without the need for confirmatory testing.
The New York-based multinational investment company will acquire Ancestry from current stakeholders Silver Lake, Spectrum Equity, Permira, and others.
The next iteration of Ancestry's Health experience seeks to provide customers with actionable information about certain commonly inherited health conditions.
Data collected from volunteers will be used in a genome-wide association study to better understand COVID-19.
Some of the market's most influential voices, including Kári Stefánsson and Linda Avey, believe that consumer genomics is not on the way out but rather experiencing a period of transition.
The company will offer a 32-gene polygenic score test to patients in the Osaka, Japan Nakanoshima Clinic, with reporting and patient support help from IxLayer.
CEO Margo Georgiadis said that the company has "seen a slowdown in consumer demand across the entire DNA category."
The company hopes to help consumer genomics firms and healthcare companies reduce the IT burdens associated with launching a new test.
The fledgling company, started as a promise to the founder's dying sister, is trying to succeed in a consumer niche where so many others have failed.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.